Format

Send to

Choose Destination
Mol Immunol. 2015 Oct;67(2 Pt A):4-17. doi: 10.1016/j.molimm.2015.02.009. Epub 2015 Mar 5.

Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy.

Author information

1
Division of Hematology and Oncology, Mayo Clinic, 4500 San Pablo Rd., Jacksonville, FL, USA.
2
Division of Hematology and Oncology, Mayo Clinic, 4500 San Pablo Rd., Jacksonville, FL, USA. Electronic address: Joseph.Richard@Mayo.edu.

Abstract

Immunotherapy for the treatment of cancer is rapidly evolving from therapies that globally and non-specifically simulate the immune system to more targeted activation of individual components of the immune system. The net result of this targeted approach is decreased toxicity and increased efficacy of immunotherapy. More specifically, therapies that inhibit the interaction between programmed death ligand 1 (PD-L1), present on the surface of tumor or antigen-presenting cells, and programmed death 1 (PD-1), present on the surface of activated lymphocytes, are generating much excitement and enthusiasm, even in malignancies that are not traditionally considered to be immunogenic. Herein, we review the current landscape of anti-PD-1 and anti-PD-L1 therapies in the world of oncology. We have performed a comprehensive literature search on the data available through PubMed, Medline, Scopus, the ClinicalTrials.gov registry, and abstracts from major oncology meetings in order to summarize the clinical data of anti-PD-1/PD-L1 therapies.

KEYWORDS:

Cancer; Immune evasion; Immunotherapy; PD-1; PD-L1

PMID:
25749122
DOI:
10.1016/j.molimm.2015.02.009
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center